ScoreWhy is Chengdu Olymvax Biopharmaceuticals, Inc. ?
1
With a growth in Net Sales of 25.38%, the company declared Very Positive results in Sep 25
- The company has declared positive results for the last 2 consecutive quarters
- ROCE(HY) Highest at 6.86%
- INTEREST COVERAGE RATIO(Q) Highest at 1,289.5
- RAW MATERIAL COST(Y) Fallen by -2.66% (YoY)
2
Market Beating performance in long term as well as near term
- Along with generating 103.83% returns in the last 1 year, the stock has outperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Chengdu Olymvax Biopharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Chengdu Olymvax Biopharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Chengdu Olymvax Biopharmaceuticals, Inc.
99.21%
2.70
63.41%
China Shanghai Composite
16.1%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
17.39%
EBIT Growth (5y)
-4.86%
EBIT to Interest (avg)
15.30
Debt to EBITDA (avg)
0.61
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.46
Tax Ratio
15.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.29%
ROE (avg)
4.40%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
173
Industry P/E
Price to Book Value
11.18
EV to EBIT
162.83
EV to EBITDA
101.91
EV to Capital Employed
9.46
EV to Sales
15.88
PEG Ratio
0.75
Dividend Yield
NA
ROCE (Latest)
5.81%
ROE (Latest)
6.45%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
ROCE(HY)
Highest at 6.86%
INTEREST COVERAGE RATIO(Q)
Highest at 1,289.5
RAW MATERIAL COST(Y)
Fallen by -2.66% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 0.84 times
DEBTORS TURNOVER RATIO(HY)
Highest at 1.18 times
NET SALES(Q)
At CNY 201.07 MM has Grown at 25.38%
PRE-TAX PROFIT(Q)
Highest at CNY 41.07 MM
NET PROFIT(Q)
Highest at CNY 34.28 MM
EPS(Q)
Highest at CNY 0.08
-2What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at 18.69 %
Here's what is working for Chengdu Olymvax Biopharmaceuticals, Inc.
Interest Coverage Ratio
Highest at 1,289.5
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales
At CNY 201.07 MM has Grown at 25.38%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Pre-Tax Profit
Highest at CNY 41.07 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 34.28 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.08
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Inventory Turnover Ratio
Highest at 0.84 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 1.18 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -2.66% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Chengdu Olymvax Biopharmaceuticals, Inc.
Debt-Equity Ratio
Highest at 18.69 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
